Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

SOHO 2020 | Targeting p53 in MDS

David Sallman • 2 Sep 2020
SOHO 2020
Myelodysplastic Syndromes Azacitidine Decitabine

David Sallman, MD, H. Lee Moffitt Cancer Center, Tampa, FL, discusses p53 mutations in the context of patients with myelodysplastic syndromes (MDS) and it’s association with survival. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from David Sallman

HMA maintenance therapy in TP53-mutated AML and MDS improves outcomes of transplantation 1:32
HMA maintenance therapy in TP53-mutated AML and MDS improves outcomes of transplantation
David Sallman • 5 Dec 2025
Pivekimab sunirine in combination with venetoclax plus azacitidine in unfit, newly diagnosed AML 2:19
Pivekimab sunirine in combination with venetoclax plus azacitidine in unfit, newly diagnosed AML
David Sallman • 5 Dec 2025
Advances in menin inhibition for AML: experience with revumenib and recent approval of ziftomenib 1:56
Advances in menin inhibition for AML: experience with revumenib and recent approval of ziftomenib
David Sallman • 5 Dec 2025
Approaching TP53-mutated AML: current challenges, ongoing research & novel therapeutic strategies 16:15
Approaching TP53-mutated AML: current challenges, ongoing research & novel therapeutic strategies
Andrew Wei et al. • 19 Sep 2025

Related Videos

Updated results from a Phase II trial of elritercept in LR-MDS 2:27
Updated results from a Phase II trial of elritercept in LR-MDS
Lynette Chee • 8 Dec 2025
Improving diagnostic procedures in MDS to avoid invasive bone marrow examination 3:53
Improving diagnostic procedures in MDS to avoid invasive bone marrow examination
Moshe Mittelman • 7 Dec 2025
Correlation between treatment-emergent cytopenias and clinical response with imetelstat in LR-MDS 1:10
Correlation between treatment-emergent cytopenias and clinical response with imetelstat in LR-MDS
Amer Zeidan • 5 Dec 2025
Luspatercept initiated at the maximum-approved dose in transfusion-dependent LR-MDS: MAXILUS trial 1:11
Luspatercept initiated at the maximum-approved dose in transfusion-dependent LR-MDS: MAXILUS trial
Amer Zeidan • 5 Dec 2025
The content of VJHemOnc is intended for healthcare professionals